Overview

A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants

Status:
Completed

Trial end date:
2018-02-08

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics after a single dose of dexlansoprazole 30 and 60 mg delayed-release capsules in healthy Chinese participants.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Dexlansoprazole
Lansoprazole